跳至主要内容
临床试验/NL-OMON52654
NL-OMON52654招募中4 期

De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring - FREE-study

niversitair Medisch Centrum Groningen0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
12 至 64(—)

入选标准

  • - Aged 12-25 years
  • - Diagnosed with luminal Crohn*s disease or ulcerative colitis
  • - Treated with either 8-weekly infliximab or 2-weekly adalimumab
  • - Current anti-TNF agent as first ever anti-TNF agent or prior anti-TNF agent
  • discontinued for reason other than primary non-response or secondary
  • loss-of-response
  • - No previous attempts to lengthen the dosing interval
  • - Three consecutive faecal calprotectin (FC) results in the target range (i.e.
  • <250 µg/g for CD patients; <150 µg/g for UC patients) in the previous 6 months
  • NL73966.042.20 / FREE-study (v3.6)
  • confirmed endoscopic remission within 2 months before study entry (i.e. simple
  • endoscopic score for Crohn*s disease (SES-CD) <3 points; ulcerative colitis
  • endoscopic index of severity (UCEIS) <=1 point or Mayo endoscopic subscore <=1
  • - Absence of symptoms associated with active IBD (judged by the local IBD-team)
  • - Written informed consent granted

排除标准

  • - Perianal fistula
  • - Presence of ileostomy or ileoanal pouch
  • - Any inflammatory comorbidity, such as rheumatoid arthritis
  • - Current treatment with corticosteroids (prednisone or budesonide)
  • - Current pregnancy

研究者

相似试验

De-escalation of anti-TNF therapy in adolescents and... | 临床试验